Literature DB >> 1893635

Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cell-mediated immune response.

P McCulloch1, G Gallagher, L P Walsh, Y Zaloom, J Xie.   

Abstract

The ability of LAK cells and/or IL-2 to affect the course of an established T cell response was examined in a delayed-type hypersensitivity (DTH) model. IL-2 greatly increased the magnitude of the response at 24 h, while LAK cells alone had no effect. The administration of LAK cells and IL-2 together also had no effect on the magnitude of the DTH response, demonstrating that LAK cells were able to remove the enhancement seen with IL-2 alone. The presence of LAK cells reduced the serum half-life of IL-2 significantly, but not to an extent able to account for the observed loss of IL-2 induced DTH enhancement. IL-2 administration influenced cell phenotypes in the spleen and draining lymph nodes (DLN), as well as increasing splenic weight; the additional presence of LAK cells markedly altered these effects of IL-2 in the spleen (but not the DLN). Taken together, these results suggest that LAK cells interact with activated T-cells within the immune system and modulate their function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1893635      PMCID: PMC1535602          DOI: 10.1111/j.1365-2249.1991.tb05760.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Recent advances in cellular immunology: implications for immunity to cancer.

Authors:  M T Lotze; O J Finn
Journal:  Immunol Today       Date:  1990-06

2.  In vivo administration of Interleukin-2 enhances specific alloimmune responses.

Authors:  S A Rosenberg; P J Spiess; S Schwarz
Journal:  Transplantation       Date:  1983-06       Impact factor: 4.939

3.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

4.  Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.

Authors:  S E Ettinghausen; E H Lipford; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

5.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Authors:  S L Topalian; L M Muul; D Solomon; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

6.  Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome.

Authors:  R S Cotran; J S Pober; M A Gimbrone; T A Springer; E A Wiebke; A A Gaspari; S A Rosenberg; M T Lotze
Journal:  J Immunol       Date:  1988-03-15       Impact factor: 5.422

7.  Systemic administration of recombinant human interleukin-2 in mice.

Authors:  A E Chang; C L Hyatt; S A Rosenberg
Journal:  J Biol Response Mod       Date:  1984-10

8.  Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate.

Authors:  M Malkovský; P B Medawar; D R Thatcher; J Toy; R Hunt; L S Rayfield; C Doré
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

9.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

10.  Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

Authors:  E A Grimm; R J Robb; J A Roth; L M Neckers; L B Lachman; D J Wilson; S A Rosenberg
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.